The company emphasized that the partial hold was due to "additional questions" about the study, including the delivery device being used, and was not related to any adverse events. As such, the Phase I study of the vaccine, INO-4800, is proceeding.
A synthetic vaccine developer is using a $750,000 small business innovation research grant from the U.S. Department of Defense to test the safety of its electrical drug delivery method with its DNA vaccines to guard against bioterrorism, according to a company statement. The drug delivery system from Inovio Pharmaceuticals (NYSE AMEX:INO) uses an electrical charge […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A synthetic vaccine developer has added a former Merck vaccines president to its board of directors. Dr. Adel A.F. Mahmoud joined the board of Inovio Pharmaceuticals (NYSE AMEX:INO) this week. He served as president of Merck Vaccines as well as Merck’s chief medical adviser for vaccines and infectious diseases for six years until 2005. For […]
Inovio Pharmaceuticals (NYSE:INO) has closed a public offering in which it raised $4 million. It said in a statement that it will use the proceeds toward clinical trial and research and development expenses. Inovio Pharmaceuticals, a Blue Bell, Pennsylvania synthetic vaccine developer, has three drugs in phase 2 clinical trials for cervical cancer, HIV and […]
Dr. Joseph Kim is the CEO of Inovio Pharmaceuticals, a Blue Bell, Pennsylvania synthetic vaccine developer that has three drugs in Phase 2 clinical trials for cervical cancer, HIV, and malaria. It started life as VGX Pharmaceuticals which Kim launched with his PhD professor David Weiner of the Perelman School of Medicine at the University […]
Inovio Pharmaceuticals (NYSE AMEX: INO) has teamed up with affiliate VGX International to finance clinical development of the Blue Bell, Pennsylvania-based drug developer’s therapeutic vaccines for hepatitis B and C infections. Under the terms of the deal, VGX will receive marketing rights for the vaccines in Asia, but Inovio will hold onto the lucrative Japanese […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.